Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: Results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)
Annals of Rheumatic Diseases Dec 05, 2017
Nakaoka Y, et al. - Tocilizumab, an interleukin-6 receptor antibody, was tested for efficacy and safety in patients with Takayasu arteritis (TAK). Tocilizumab was favoured over placebo for time to relapse of TAK without new safety concerns, however, the primary endpoint was not met.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
